.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
IMPROVE-IT provided randomized evidence that adding ezetimibe to statin therapy after acute coronary syndrome can further reduce cardiovascular events. More than 18,000 patients were randomized to simvastatin plus ezetimibe or simvastatin alone and followed for several years. The combination produced a modest but statistically significant reduction in the primary composite cardiovascular endpoint, accompanied by greater LDL-cholesterol lowering. For general physicians, the study reinforces the principle that cumulative LDL exposure matters and that treatment escalation can be justified when statin therapy alone does not achieve the desired lipid reduction. The trial also helped establish ezetimibe as a practical first add-on therapy because of its oral administration, tolerability and evidence base. In patients with atherosclerotic cardiovascular disease, lipid management should therefore move beyond “statin yes/no” and toward assessment of achieved LDL-C, treatment adherence, secondary causes and the need for additional therapy. The clinical challenge remains implementation: patients often receive lower-than-needed doses, discontinue therapy or are not rechecked after initiation. A structured lipid pathway can convert strong trial evidence into more consistent risk reduction.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
IMPROVE-IT provided randomized evidence that adding ezetimibe to statin therapy after acute coronary syndrome can further reduce cardiovascular events. More than 18,000 patients were randomized to simvastatin plus ezetimibe or simvastatin alone and followed for several years. The combination produced a modest but statistically significant reduction in the primary composite cardiovascular endpoint, accompanied by greater LDL-cholesterol lowering. For general physicians, the study reinforces the principle that cumulative LDL exposure matters and that treatment escalation can be justified when statin therapy alone does not achieve the desired lipid reduction. The trial also helped establish ezetimibe as a practical first add-on therapy because of its oral administration, tolerability and evidence base. In patients with atherosclerotic cardiovascular disease, lipid management should therefore move beyond “statin yes/no” and toward assessment of achieved LDL-C, treatment adherence, secondary causes and the need for additional therapy. The clinical challenge remains implementation: patients often receive lower-than-needed doses, discontinue therapy or are not rechecked after initiation. A structured lipid pathway can convert strong trial evidence into more consistent risk reduction.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
